A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice

Marcin Sadowski, Joanna Pankiewicz, Henrieta Scholtzova, James A. Ripellino, Yongsheng Li, Stephen D. Schmidt, Paul M. Mathews, John D. Fryer, David M. Holtzman, Einar M. Sigurdsson, Thomas Wisniewski

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is associated with accumulation of β-amyloid (Aβ). A major genetic risk factor for sporadic AD is inheritance of the apolipoprotein (apo) E4 allele. ApoE can act as a pathological chaperone of Aβ, promoting its conformational transformation from soluble Aβ into toxic aggregates. We determined if blocking the apoE/Aβ interaction reduces Aβ load in transgenic (Tg) AD mice. The binding site of apoE on Aβ corresponds to residues 12 to 28. To block binding, we synthesized a peptide containing these residues, but substituted valine at position 18 to proline (Aβl2-28P). This changed the peptide's properties, making it non-fibrillogenic and non-toxic. Aβl2-28P competitively blocks binding of full-length Aβ to apoE (IC50 = 36.7 nmol). Furthermore, Aβl2-28P reduces Aβ fibrillogenesis in the presence of apoE, and Aβ/apoE toxicity in cell culture. Aβl2-28P is blood-brain barrier-permeable and in AD Tg mice inhibits Aβ deposition. Tg mice treated with Aβ12-28P for 1 month had a 63-3% reduction in Aβ load in the cortex (P = 0.0043) and a 59.5% (P = 0.0087) reduction in the hippocampus comparing to age-matched control Tg mice. Antibodies against Aβ were not detected in sera of treated mice; therefore the observed therapeutic effect of Aβl2-28P cannot be attributed to an antibody clearance response. Our experiments demonstrate that compounds blocking the interaction between Aβ and its pathological chaperons may be beneficial for treatment of β-amyloid deposition in AD.

Original languageEnglish (US)
Pages (from-to)937-948
Number of pages12
JournalAmerican Journal of Pathology
Volume165
Issue number3
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Amyloid Plaques
Apolipoproteins E
Amyloid
Transgenic Mice
Alzheimer Disease
Peptides
Apolipoprotein E4
compound A 12
Poisons
Valine
Therapeutic Uses
Blood-Brain Barrier
Proline
Inhibitory Concentration 50
Antibody Formation
In Vitro Techniques
Hippocampus
Cell Culture Techniques
Alleles
Binding Sites

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice. / Sadowski, Marcin; Pankiewicz, Joanna; Scholtzova, Henrieta; Ripellino, James A.; Li, Yongsheng; Schmidt, Stephen D.; Mathews, Paul M.; Fryer, John D.; Holtzman, David M.; Sigurdsson, Einar M.; Wisniewski, Thomas.

In: American Journal of Pathology, Vol. 165, No. 3, 09.2004, p. 937-948.

Research output: Contribution to journalArticle

Sadowski, M, Pankiewicz, J, Scholtzova, H, Ripellino, JA, Li, Y, Schmidt, SD, Mathews, PM, Fryer, JD, Holtzman, DM, Sigurdsson, EM & Wisniewski, T 2004, 'A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice', American Journal of Pathology, vol. 165, no. 3, pp. 937-948.
Sadowski, Marcin ; Pankiewicz, Joanna ; Scholtzova, Henrieta ; Ripellino, James A. ; Li, Yongsheng ; Schmidt, Stephen D. ; Mathews, Paul M. ; Fryer, John D. ; Holtzman, David M. ; Sigurdsson, Einar M. ; Wisniewski, Thomas. / A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice. In: American Journal of Pathology. 2004 ; Vol. 165, No. 3. pp. 937-948.
@article{29c6af8150e1496a9c020624777a91a8,
title = "A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice",
abstract = "Alzheimer's disease (AD) is associated with accumulation of β-amyloid (Aβ). A major genetic risk factor for sporadic AD is inheritance of the apolipoprotein (apo) E4 allele. ApoE can act as a pathological chaperone of Aβ, promoting its conformational transformation from soluble Aβ into toxic aggregates. We determined if blocking the apoE/Aβ interaction reduces Aβ load in transgenic (Tg) AD mice. The binding site of apoE on Aβ corresponds to residues 12 to 28. To block binding, we synthesized a peptide containing these residues, but substituted valine at position 18 to proline (Aβl2-28P). This changed the peptide's properties, making it non-fibrillogenic and non-toxic. Aβl2-28P competitively blocks binding of full-length Aβ to apoE (IC50 = 36.7 nmol). Furthermore, Aβl2-28P reduces Aβ fibrillogenesis in the presence of apoE, and Aβ/apoE toxicity in cell culture. Aβl2-28P is blood-brain barrier-permeable and in AD Tg mice inhibits Aβ deposition. Tg mice treated with Aβ12-28P for 1 month had a 63-3{\%} reduction in Aβ load in the cortex (P = 0.0043) and a 59.5{\%} (P = 0.0087) reduction in the hippocampus comparing to age-matched control Tg mice. Antibodies against Aβ were not detected in sera of treated mice; therefore the observed therapeutic effect of Aβl2-28P cannot be attributed to an antibody clearance response. Our experiments demonstrate that compounds blocking the interaction between Aβ and its pathological chaperons may be beneficial for treatment of β-amyloid deposition in AD.",
author = "Marcin Sadowski and Joanna Pankiewicz and Henrieta Scholtzova and Ripellino, {James A.} and Yongsheng Li and Schmidt, {Stephen D.} and Mathews, {Paul M.} and Fryer, {John D.} and Holtzman, {David M.} and Sigurdsson, {Einar M.} and Thomas Wisniewski",
year = "2004",
month = "9",
language = "English (US)",
volume = "165",
pages = "937--948",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice

AU - Sadowski, Marcin

AU - Pankiewicz, Joanna

AU - Scholtzova, Henrieta

AU - Ripellino, James A.

AU - Li, Yongsheng

AU - Schmidt, Stephen D.

AU - Mathews, Paul M.

AU - Fryer, John D.

AU - Holtzman, David M.

AU - Sigurdsson, Einar M.

AU - Wisniewski, Thomas

PY - 2004/9

Y1 - 2004/9

N2 - Alzheimer's disease (AD) is associated with accumulation of β-amyloid (Aβ). A major genetic risk factor for sporadic AD is inheritance of the apolipoprotein (apo) E4 allele. ApoE can act as a pathological chaperone of Aβ, promoting its conformational transformation from soluble Aβ into toxic aggregates. We determined if blocking the apoE/Aβ interaction reduces Aβ load in transgenic (Tg) AD mice. The binding site of apoE on Aβ corresponds to residues 12 to 28. To block binding, we synthesized a peptide containing these residues, but substituted valine at position 18 to proline (Aβl2-28P). This changed the peptide's properties, making it non-fibrillogenic and non-toxic. Aβl2-28P competitively blocks binding of full-length Aβ to apoE (IC50 = 36.7 nmol). Furthermore, Aβl2-28P reduces Aβ fibrillogenesis in the presence of apoE, and Aβ/apoE toxicity in cell culture. Aβl2-28P is blood-brain barrier-permeable and in AD Tg mice inhibits Aβ deposition. Tg mice treated with Aβ12-28P for 1 month had a 63-3% reduction in Aβ load in the cortex (P = 0.0043) and a 59.5% (P = 0.0087) reduction in the hippocampus comparing to age-matched control Tg mice. Antibodies against Aβ were not detected in sera of treated mice; therefore the observed therapeutic effect of Aβl2-28P cannot be attributed to an antibody clearance response. Our experiments demonstrate that compounds blocking the interaction between Aβ and its pathological chaperons may be beneficial for treatment of β-amyloid deposition in AD.

AB - Alzheimer's disease (AD) is associated with accumulation of β-amyloid (Aβ). A major genetic risk factor for sporadic AD is inheritance of the apolipoprotein (apo) E4 allele. ApoE can act as a pathological chaperone of Aβ, promoting its conformational transformation from soluble Aβ into toxic aggregates. We determined if blocking the apoE/Aβ interaction reduces Aβ load in transgenic (Tg) AD mice. The binding site of apoE on Aβ corresponds to residues 12 to 28. To block binding, we synthesized a peptide containing these residues, but substituted valine at position 18 to proline (Aβl2-28P). This changed the peptide's properties, making it non-fibrillogenic and non-toxic. Aβl2-28P competitively blocks binding of full-length Aβ to apoE (IC50 = 36.7 nmol). Furthermore, Aβl2-28P reduces Aβ fibrillogenesis in the presence of apoE, and Aβ/apoE toxicity in cell culture. Aβl2-28P is blood-brain barrier-permeable and in AD Tg mice inhibits Aβ deposition. Tg mice treated with Aβ12-28P for 1 month had a 63-3% reduction in Aβ load in the cortex (P = 0.0043) and a 59.5% (P = 0.0087) reduction in the hippocampus comparing to age-matched control Tg mice. Antibodies against Aβ were not detected in sera of treated mice; therefore the observed therapeutic effect of Aβl2-28P cannot be attributed to an antibody clearance response. Our experiments demonstrate that compounds blocking the interaction between Aβ and its pathological chaperons may be beneficial for treatment of β-amyloid deposition in AD.

UR - http://www.scopus.com/inward/record.url?scp=4344659648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344659648&partnerID=8YFLogxK

M3 - Article

C2 - 15331417

AN - SCOPUS:4344659648

VL - 165

SP - 937

EP - 948

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -